Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904588 · ClinicalTrials.gov registry record · Phase 2
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
A Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Center for International Blood and Marrow Transplant Research.
- Active
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT04904588: Active Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Center for International Blood and Marrow Transplant Research.
NCT04904588 is a Phase 2 study of Lymphoma and Myelodysplastic Syndromes that is active but no longer recruiting, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 300 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04904588, a Phase 2 study of Lymphoma and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Center for International Blood and Marrow Transplant Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total-body irradiation
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Francisco - San Francisco
- Stanford University - Stanford
Florida
- University of Florida Health Shands Hospital - Gainesville
- University of Miami Sylvester Cancer Center - Miami
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Children's Healthcare of Atlanta - Atlanta
- Emory University Medical Center - Atlanta
Illinois
- Northwestern University - Chicago
- The University of Chicago - Chicago
Maryland
- University of Maryland Medical Center - Baltimore
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Tufts Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Medical Center - Mott Children's Hospita - Ann Arbor
- Karmanos Cancer Institute - Detroit
Colorado
- Colorado Blood Cancer Institute - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04904588 still lists
NCT04904588 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower).
The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04904588 names 20 study sites across 11 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04904588 about?
NCT04904588 is a clinical study titled "HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide". This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamid...
What is the current status of trial NCT04904588?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2021-09-30. Estimated completion is 2026-12.
What conditions does trial NCT04904588 study?
This clinical trial studies the following conditions: Lymphoma, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT04904588?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Total-body irradiation (RADIATION).
Who is sponsoring clinical trial NCT04904588?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04904588 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04904588's enrollment target sits among peer trials
300 32nd of 299 higher than 266 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI